286 related articles for article (PubMed ID: 23317189)
1. Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma.
Inandiklioğlu N; Yilmaz S; Demirhan O; Erdoğan S; Tanyeli A
Asian Pac J Cancer Prev; 2012; 13(11):5391-7. PubMed ID: 23317189
[TBL] [Abstract][Full Text] [Related]
2. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
3. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
Chen QR; Bilke S; Wei JS; Whiteford CC; Cenacchi N; Krasnoselsky AL; Greer BT; Son CG; Westermann F; Berthold F; Schwab M; Catchpoole D; Khan J
BMC Genomics; 2004 Sep; 5():70. PubMed ID: 15380028
[TBL] [Abstract][Full Text] [Related]
4. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
5. Boolean modeling identifies Greatwall/MASTL as an important regulator in the AURKA network of neuroblastoma.
Dahlhaus M; Burkovski A; Hertwig F; Mussel C; Volland R; Fischer M; Debatin KM; Kestler HA; Beltinger C
Cancer Lett; 2016 Feb; 371(1):79-89. PubMed ID: 26616283
[TBL] [Abstract][Full Text] [Related]
6. Investigation of MYCN status in neuroblastoma by fluorescence in situ hybridization.
Wan TS; Ma ES; Chan GC; Chan LC
Int J Mol Med; 2004 Dec; 14(6):981-7. PubMed ID: 15547663
[TBL] [Abstract][Full Text] [Related]
7. 8q deletion in MYCN-amplified neuroblastoma of a child born from assisted reproductive technology.
Brassesco MS; Valera ET; de Oliveira FM; de Paula Queiroz RG; Scrideli CA; Sakamoto-Hojo ET; Tone LG
J Pediatr Hematol Oncol; 2009 Mar; 31(3):215-9. PubMed ID: 19262252
[TBL] [Abstract][Full Text] [Related]
8. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM
Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568
[TBL] [Abstract][Full Text] [Related]
9. Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes.
Fix A; Lucchesi C; Ribeiro A; Lequin D; Pierron G; Schleiermacher G; Delattre O; Janoueix-Lerosey I
Genes Chromosomes Cancer; 2008 Oct; 47(10):819-34. PubMed ID: 18553563
[TBL] [Abstract][Full Text] [Related]
10. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.
Mosquera JM; Beltran H; Park K; MacDonald TY; Robinson BD; Tagawa ST; Perner S; Bismar TA; Erbersdobler A; Dhir R; Nelson JB; Nanus DM; Rubin MA
Neoplasia; 2013 Jan; 15(1):1-10. PubMed ID: 23358695
[TBL] [Abstract][Full Text] [Related]
11. Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.
Berbegall AP; Villamón E; Piqueras M; Tadeo I; Djos A; Ambros PF; Martinsson T; Ambros IM; Cañete A; Castel V; Navarro S; Noguera R
Oncogene; 2016 Mar; 35(11):1423-32. PubMed ID: 26119945
[TBL] [Abstract][Full Text] [Related]
12. Concomitant DDX1 and MYCN gain in neuroblastoma.
Defferrari R; Tonini GP; Conte M; Papio F; Sementa AR; Valent A; Schena F; Perri P; Mazzocco K
Cancer Lett; 2007 Oct; 256(1):56-63. PubMed ID: 17611020
[TBL] [Abstract][Full Text] [Related]
13. Characterization of karyotypic events and evolution in neuroblastoma.
Betts DR; Cohen N; Leibundgut KE; Kühne T; Caflisch U; Greiner J; Traktenbrot L; Niggli FK
Pediatr Blood Cancer; 2005 Feb; 44(2):147-57. PubMed ID: 15390360
[TBL] [Abstract][Full Text] [Related]
14. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma.
Weber A; Imisch P; Bergmann E; Christiansen H
J Clin Oncol; 2004 Jul; 22(13):2681-90. PubMed ID: 15226335
[TBL] [Abstract][Full Text] [Related]
15. Constitutional 11q14-q22 chromosome deletion syndrome in a child with neuroblastoma MYCN single copy.
Passariello A; De Brasi D; Defferrari R; Genesio R; Tufano M; Mazzocco K; Capasso M; Migliorati R; Martinsson T; Siani P; Nitsch L; Tonini GP
Eur J Med Genet; 2013 Nov; 56(11):626-34. PubMed ID: 24035971
[TBL] [Abstract][Full Text] [Related]
16. MYCN overexpression is associated with unbalanced copy number gain, altered nuclear location, and overexpression of chromosome arm 17q genes in neuroblastoma tumors and cell lines.
Kuzyk A; Booth S; Righolt C; Mathur S; Gartner J; Mai S
Genes Chromosomes Cancer; 2015 Oct; 54(10):616-28. PubMed ID: 26171843
[TBL] [Abstract][Full Text] [Related]
17. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
[TBL] [Abstract][Full Text] [Related]
18. The genetic and clinical significance of MYCN gain as detected by FISH in neuroblastoma.
Souzaki R; Tajiri T; Teshiba R; Higashi M; Kinoshita Y; Tanaka S; Taguchi T
Pediatr Surg Int; 2011 Mar; 27(3):231-6. PubMed ID: 21046119
[TBL] [Abstract][Full Text] [Related]
19. Alterations in p16 and p53 genes and chromosomal findings in patients with lung cancer: fluorescence in situ hybridization and cytogenetic studies.
Demirhan O; Taştemir D; Hastürk S; Kuleci S; Hanta I
Cancer Epidemiol; 2010 Aug; 34(4):472-7. PubMed ID: 20444664
[TBL] [Abstract][Full Text] [Related]
20. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
Thompson D; Vo KT; London WB; Fischer M; Ambros PF; Nakagawara A; Brodeur GM; Matthay KK; DuBois SG
Cancer; 2016 Mar; 122(6):935-45. PubMed ID: 26709890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
